ClaudioVentrella/iStock by way of Getty Pictures
Chinese language medtech Baird Medical (BDMD) plans to go public by a merger with SPAC ExcelFin Acquisition Corp. (NASDAQ:XFIN).
The deal pegs the enterprise worth of the mixed firm at $370M, with shares anticipated to commerce on Nasdaq beneath the image BDMD.
Headquartered in Guangzhou, Baird is a number one developer and supplier of microwave ablation units in China. The corporate is predicted to report 2023 internet earnings of $18M on income of $45M. For 2022, Baird reported income of $35M, in keeping with the businesses.
Extra on healthcare SPACs:
AUM Biosciences terminates merger with SPAC Mountain Crest V
TNL Mediagene to go public on Nasdaq by way of enterprise combo with web and media SPAC Blue Ocean Acquisition
SPAC Phoenix Biotech to merge with immunology drug developer CERo
